Jameson D Voss1, Martin Skarzynski2, Erin M McAuley2, Ezekiel J Maier2, Thomas Gibbons3, Anthony C Fries4, Richard R Chapleau4. 1. US Air Force Medical Readiness Agency, Falls Church, VA 22042, USA. 2. Booz Allen Hamilton, Bethesda, MD 20814, USA. 3. 59th Medical Wing, Joint Base San Antonio, TX 78234, USA. 4. Public Health and Preventive Medicine Department, US Air Force School of Aerospace Medicine, Wright Patterson AFB, OH 45433, USA.
Abstract
INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic is a global public health emergency causing a disparate burden of death and disability around the world. The viral genetic variants associated with outcome severity are still being discovered. METHODS: We downloaded 155 958 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes from GISAID. Of these genomes, 3637 samples included useable metadata on patient outcomes. Using this subset, we evaluated whether SARS-CoV-2 viral genomic variants improved prediction of reported severity beyond age and region. First, we established whether including genomic variants as model features meaningfully increased the predictive power of our model. Next, we evaluated specific variants in order to determine the magnitude of association with severity and the frequency of these variants among SARS-CoV-2 genomes. RESULTS: Logistic regression models that included viral genomic variants outperformed other models (area under the curve = 0.91 as compared with 0.68 for age and gender alone; P < 0.001). We found 84 variants with odds ratios greater than 2 for outcome severity (17 and 67 for higher and lower severity, respectively). The median frequency of associated variants was 0.15% (interquartile range 0.09-0.45%). Altogether 85% of genomes had at least one variant associated with patient outcome. CONCLUSION: Numerous SARS-CoV-2 variants have 2-fold or greater association with odds of mild or severe outcome and collectively, these variants are common. In addition to comprehensive mitigation efforts, public health measures should be prioritized to control the more severe manifestations of COVID-19 and the transmission chains linked to these severe cases.Lay summary: This study explores which, if any, SARS-CoV-2 viral genomic variants are associated with mild or severe COVID-19 patient outcomes. Our results suggest that there are common genomic variants in SARS-CoV-2 that are more often associated with negative patient outcomes, which may impact downstream public health measures. Published by Oxford University Press on behalf of the Foundation for Evolution, Medicine, and Public Health 2021. This work is written by a US Government employee and is in the public domain in the US.
INTRODUCTION: The coronavirus disease 2019 (COVID-19) pandemic is a global public health emergency causing a disparate burden of death and disability around the world. The viral genetic variants associated with outcome severity are still being discovered. METHODS: We downloaded 155 958 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) genomes from GISAID. Of these genomes, 3637 samples included useable metadata on patient outcomes. Using this subset, we evaluated whether SARS-CoV-2 viral genomic variants improved prediction of reported severity beyond age and region. First, we established whether including genomic variants as model features meaningfully increased the predictive power of our model. Next, we evaluated specific variants in order to determine the magnitude of association with severity and the frequency of these variants among SARS-CoV-2 genomes. RESULTS: Logistic regression models that included viral genomic variants outperformed other models (area under the curve = 0.91 as compared with 0.68 for age and gender alone; P < 0.001). We found 84 variants with odds ratios greater than 2 for outcome severity (17 and 67 for higher and lower severity, respectively). The median frequency of associated variants was 0.15% (interquartile range 0.09-0.45%). Altogether 85% of genomes had at least one variant associated with patient outcome. CONCLUSION: Numerous SARS-CoV-2 variants have 2-fold or greater association with odds of mild or severe outcome and collectively, these variants are common. In addition to comprehensive mitigation efforts, public health measures should be prioritized to control the more severe manifestations of COVID-19 and the transmission chains linked to these severe cases.Lay summary: This study explores which, if any, SARS-CoV-2 viral genomic variants are associated with mild or severe COVID-19 patient outcomes. Our results suggest that there are common genomic variants in SARS-CoV-2 that are more often associated with negative patient outcomes, which may impact downstream public health measures. Published by Oxford University Press on behalf of the Foundation for Evolution, Medicine, and Public Health 2021. This work is written by a US Government employee and is in the public domain in the US.
Authors: Lorenzo Subissi; Clara C Posthuma; Axelle Collet; Jessika C Zevenhoven-Dobbe; Alexander E Gorbalenya; Etienne Decroly; Eric J Snijder; Bruno Canard; Isabelle Imbert Journal: Proc Natl Acad Sci U S A Date: 2014-09-02 Impact factor: 11.205
Authors: Pablo Cingolani; Viral M Patel; Melissa Coon; Tung Nguyen; Susan J Land; Douglas M Ruden; Xiangyi Lu Journal: Front Genet Date: 2012-03-15 Impact factor: 4.599
Authors: Sarah R Leist; Kenneth H Dinnon; Alexandra Schäfer; Longping V Tse; Kenichi Okuda; Yixuan J Hou; Ande West; Caitlin E Edwards; Wes Sanders; Ethan J Fritch; Kendra L Gully; Trevor Scobey; Ariane J Brown; Timothy P Sheahan; Nathaniel J Moorman; Richard C Boucher; Lisa E Gralinski; Stephanie A Montgomery; Ralph S Baric Journal: Cell Date: 2020-09-23 Impact factor: 41.582
Authors: Anastasis Oulas; Maria Zanti; Marios Tomazou; Margarita Zachariou; George Minadakis; Marilena M Bourdakou; Pavlos Pavlidis; George M Spyrou Journal: PLoS One Date: 2021-01-26 Impact factor: 3.240
Authors: Vincent Chin; Noelle I Samia; Roman Marchant; Ori Rosen; John P A Ioannidis; Martin A Tanner; Sally Cripps Journal: Eur J Epidemiol Date: 2020-08-11 Impact factor: 8.082
Authors: Pauli Virtanen; Ralf Gommers; Travis E Oliphant; Matt Haberland; Tyler Reddy; David Cournapeau; Evgeni Burovski; Pearu Peterson; Warren Weckesser; Jonathan Bright; Stéfan J van der Walt; Matthew Brett; Joshua Wilson; K Jarrod Millman; Nikolay Mayorov; Andrew R J Nelson; Eric Jones; Robert Kern; Eric Larson; C J Carey; İlhan Polat; Yu Feng; Eric W Moore; Jake VanderPlas; Denis Laxalde; Josef Perktold; Robert Cimrman; Ian Henriksen; E A Quintero; Charles R Harris; Anne M Archibald; Antônio H Ribeiro; Fabian Pedregosa; Paul van Mulbregt Journal: Nat Methods Date: 2020-02-03 Impact factor: 28.547
Authors: Daniel Antonio Negrón; June Kang; Shane Mitchell; Mitchell Y Holland; Stephen Wist; Jameson Voss; Lauren Brinkac; Katharine Jennings; Stephanie Guertin; Bruce G Goodwin; Shanmuga Sozhamannan Journal: Front Public Health Date: 2022-04-28
Authors: Martin Skarzynski; Erin M McAuley; Ezekiel J Maier; Anthony C Fries; Jameson D Voss; Richard R Chapleau Journal: Glob Health Epidemiol Genom Date: 2022-05-31
Authors: Laura Manuto; Marco Grazioli; Andrea Spitaleri; Paolo Fontana; Luca Bianco; Luigi Bertolotti; Martina Bado; Giorgia Mazzotti; Federico Bianca; Francesco Onelia; Giovanni Lorenzin; Fabio Simeoni; Dejan Lazarevic; Elisa Franchin; Claudia Del Vecchio; Ilaria Dorigatti; Giovanni Tonon; Daniela Maria Cirillo; Enrico Lavezzo; Andrea Crisanti; Stefano Toppo Journal: Viruses Date: 2022-02-15 Impact factor: 5.048
Authors: Ahmed M Moustafa; William Otto; Xiaowu Gai; Utsav Pandey; Alex Ryutov; Moiz Bootwalla; Dennis T Maglinte; Lishuang Shen; David Ruble; Dejerianne Ostrow; Jeffrey S Gerber; Jennifer Dien Bard; Rebecca M Harris; Paul J Planet Journal: medRxiv Date: 2021-02-19